RT Journal Article
SR Electronic
T1 Clinical outcomes of drug-coated balloon for treatment of de novo coronary artery disease with and without diabetes
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 1347
OP 1353
DO 10.15537/smj.2022.43.12.20220534
VO 43
IS 12
A1 Zhang, Zhaoqian
A1 Tan, Qiang
A1 Zhang, Jiarui
A1 Wang, Xinhui
A1 Wang, Qian
YR 2022
UL http://smj.org.sa/content/43/12/1347.abstract
AB Objectives: To retrospectively evaluate the efficacy of drug-coated balloon (DCB) in patients with de novo coronary artery disease with and without diabetes.Methods: Patients with de novo coronary artery and undergoing percutaneous coronary intervention (PCI) with DCB were enrolled from March 2018 and March 2020, including 312 patients being divided into the diabetes group (n=110), pre-diabetes group (n=48) and non-diabetes group (n=154). The primary endpoint was major adverse cardiac events (MACE) (MACE; cardiovascular death, non-fatal myocardial infarction, target lesion revascularization, and target vessel revascularization) at 24 months.Results: In diabetes group, the incidence of MACE at 24 months (19.1%) was higher than in the non-diabetes group (12.5%) and pre-diabetes group (10.4%) (p<0.05). Cox regression revealed that diabetes (HR [hazard ratios] 2.049, 95% CI 1.056-4.284), bifurcation lesion (HR 5.255, 95% CI 2.765-9.986), Syntax score (HR 1.098, 95% CI 1.040-1.559) and hemoglobin A1c (HR 1.084, 95% CI 1.160-1.741) were independent predictors of MACE in patients performing PCI with DCB (all p<0.05). However, pre-diabetes did not increase the risk of MACE (HR 1.560, 95% CI 0.542-4.490, p>0.05).Conclusion: Diabetes increased the risk of MACE in patients performing PCI with DCB.